Raymond James Financial
FOLD

Raymond James Financial’s Amicus Therapeutics FOLD Stock Holding History

Raymond James Financial’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,565
Closed -$283K – 5462
2026
Q1 		$283K Buy
+19,565
New +$280K ﹤0.01% 4686
2025
Q3 		– Sell
-8,309
Closed -$47.6K – 5599
2025
Q2 		$47.6K Sell
8,309
-2,208
-21% -$14.3K ﹤0.01% 5199
2025
Q1 		$85.8K Sell
10,517
-3,466
-25% -$32.1K ﹤0.01% 4571
2024
Q4 		$132K Buy
+13,983
New +$145K ﹤0.01% 4487

Other funds holding FOLD

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Raymond James Financial's FOLD Position: Q2 2026 in Review

Raymond James Financial sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 19,565 shares — an estimated $283K sold.

Raymond James Financial first reported a position in FOLD in Q4 2024 and held it in 4 quarters. The position peaked at $283K in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

  • Raymond James Financial reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 19,565 Amicus Therapeutics shares in Q2 2026, an estimated $283K.
  • Raymond James Financial first reported a position in Amicus Therapeutics in Q4 2024 and held it in 4 quarters.
  • Raymond James Financial's Amicus Therapeutics position peaked at $283K in Q1 2026.
  • 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.